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Abstract-The administration of thyroxin to rats (500 rg daily for 2-3 weeks, 500 pg 
daily for 1 week, or 50 pg daily for 2 weeks) or triiodoth~onjne (100 pg daily for 3-5 
days) increased cardiac phosphorylase a levels. Total cardiac phosphoryiase activity 
was unchanged. Pretreatment with reserpine prevented and the @-adrenergic blocking 
agents reduced this thyroxin-induced increase in phosphorylase a. Thyroxin or 
triiodothyronine treatment potentiated the response of cardiac phosphorylase to 
exogeneously a~inistered ~t~holamines. This enhancement of the cat~hol~ine- 
induced increase in phosphorylase a could be clearly demonstrated after the animals 
were pretreated with reserpine. Dose-response relationships for these agents are 
illustrated. Glycogen analyses on the same hearts indicated a parallelism between the 
increase in phosphorylase a and the reduction in glycogen content. While hearts of 
thyroidectomized animals showed a decrease in phosphorylase a levels and an increase 
in glycogen relative to controls, the response after cat~hol~in~ was unchanged. 
These data suggest that thyroxin may enhance these catecholamine responses by modu- 
lation of the myocardial metabolic adrenergic receptor. 
THE interdependence of the action of the thyroid hormones and the catecholamines 
has been known for a long time and was recently emphasized by Brewster et uf.l who 
demonstrated the necessity of intact sympathetic pathways for certain metabolic and 
cardiovascular actions of thyroxin. This relationship has been extensively reviewed.r-s 
While the augmentation of the effects of catecholamines by the thyroid hormone has 
not been universally demonstrated,*-7 a hypothesis of thyroid action has been 
suggested by numerous investigators, which is based upon the thesis that this hormone 
either alters the effective concentration of catecholamines or regulates the magnitude 
of the response to these amines.*- 
Insight into a locus of action of the thyroid hormone has been provided by the 
observation that thyroxin elevates the Ievel of myocardial pllosphorylase u and de- 
creases myocardial glycogen.14 This present investigation is an extension of that study 
and suggests that thyroid hormone and norepinephrine interact with respect to 
* Supported by a contract from the Department of the Navy, Office of Naval Research, Nonr-1224 
(27). A preliminary report of this study has been presented in Fed. Proc. 23,562 (1964). 
t Present address: Dept. of Pharmacology, Washington University School of Medicine, St. Louis, 
MO. 
f: Dept. of Surgery, The University of Michigan Medical School, Ann Arbor, Mich. 
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myocardial phosphorylase activation and glycogen loss. It is proposed that the ob- 
served activation of cardiac phosphorylase by thyroid hormone is mediated by an 
increase in receptor sensitivity to catecholamines. 
METHODS 
White female rats (180-200 g, Holtzman strain) were used in all experiments. 
Hexobarbital sodium (120-150 mgjkg, i.p.) was used for anesthesia. 
The excised tissues were frozen in a beaker of isopentane immersed in an alcohol- 
dry ice mixture. Phosphorylase activity and glycogen content were determined on 
portions of the same tissue sample. Glycogen was isolated according to the method 
of Hassid and Abraham15 and glucose determined by the method of Nelsoni” 
Phosphorylase activity was assayed according to the method of Cori and Illing- 
worth17 as described previously. 11 Since total phosphorylase values never changed, 
phosphorylase a values are always presented as percentage of the total. 
Catecholamine infusions were performed under hexobarbital anesthesia through 
the exterior jugular vein of the rat with a Phipps and Bird model 71-045 Cme infusion 
pump having a delivery rate of 0.04 ml/min. All dilutions of catecholamines were 
made in 0.9 % NaCI-0.1 ‘A, NaHSOs and all infusions were of 5-min duration. The 
control groups not receiving the catecholamines were infused with the same volume 
of saline-bisulfite solution. Infusion of the saline-bisulfite solution alone was without 
effect on the phosphorylase a and glycogen levels of the heart. 
Thyroidectomy was performed under ether anesthesia. During the postoperative 
period the animals received 1% CaCle in their drinking water. Thyroidectomized 
animals were not used before 28 days after surgery. In the sham operated-rats, a 
midline incision was made in the neck under ether anesthesia. The thyroids were 
exposed but not removed and the incision sutured as in the thyroidectomized animals. 
All experiments were randomized on a temporal basis. At least one saline control 
and one animal receiving norepinephrine only were studied in each group. The other 
animals in the group received various treatments described below. From 6 to 16 rats 
were assayed on the same day. 
I-Thyroxin sodium (obtained from the Nutritional Biochemicals Corp.) and tri- 
iodothyronine were dissolved in alkaline isotonic saline. Solutions of the thyroid 
hormones were injected into rats daily by the S.C. route. Control animals received 
daily injections of the vehicle. Dichloroisoproterenol (DCI), administered S.C. in a 
dose of 10 mg/kg 30 min prior to sacrifice, was obtained from the Aldrich Chemical 
Co. Nethalide [2-isopropylamine-1-(2-naphthyl)ethanol hydrochloride], administered 
in a dose of 10 mg/kg S.C. 30 min prior to sacrifice, was generously supplied by Dr. 
J. W. Black, Imperial Chemical Industries, Ltd. Trimethidinium bismethosulfate 
(Ostensin, Wyeth Lab., Inc) was injected S.C. in a dose of 50 mg/kg 12 hr prior to 
sacrifice. Reserpine (2.5 mg/kg given i.p. 12 hr prior to sacrifice) was obtained from 
the Supravite Corp. Norepinephrine was diluted daily from a commercial solution 
(Levophed, Winthrop-Sterling) or from an acidified stock solution of crystalline l- 
norepinephrine obtained from Winthrop Labs. 
Data were analyzed for significance by Student’s t test and for interaction of thy- 
roid hormones with norepinephrine (potentiation) by means of the 2 x 2 factorial 
analysis of variance for unequal sample sizes. P values below 0.05 were considered to 
be statistically significant.18 
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RESULTS 
EfSect of thyroid hormone treatment on cardiac size 
The hearts from rats which received 500 pg per day of thyroxin for 2-3 weeks 
showed an average increase in wet weight of 47 per cent over control values. However, 
there was no difference in the protein concentration of the hearts in the two groups. 
Rats injected with 500 pg thyroxin daily for 1 week or 50 pg daily for 2 weeks had 
cardiac weight increases of 25 and 28 per cent, respectively, when compared to un- 
treated controls. Triiodothyronine (100 pg daily for 3-5 days) produced a 30 per cent 
increase in heart weight. Cardiac hypertrophy with thyroid hormone has been pre- 
viously observed.lg> “0 
While the daily doses ofthyroxin and triiodothyronine used in the study appear to be 
excessively large in comparison with the amount of hormone normally secreted by 
the rat, such doses were used to produce a thyrotoxic state and a significant increase 
in the cardiac phosphorylase a levels. With these treatments the animals also failed 
to gain weight at the same rate as untreated controls, although the animals so treated 
did not actually lose weight during the period of hormone treatment. 
Thyroxin-treated animals given reserpine 12 hr prior to sacrifice had an average 
body weight loss of 20 per cent during that time. Similar observations have been 
previously reported.12 This weight loss did not result entirely from a decreased food 
intake, since a similar loss was not observed in lZhr-fasted control animals similarly 
treated with reserpine. 
Phosphorylase response to thyroxin and autonomic blocking agents 
In Table 1 are shown the effects of thyroxin treatment upon cardiac phosphorylase 
a levels and glycogen content. Also shown are changes in these variables in hearts 
TABLE ~.THE INFLUENCEOFSEVERAL AUTONOMIC AGENTSON THE CARDIAC PHOS- 
PHORYLASEAND GLYCOGENRESPONSETO CHRONICTHYROXINTREATMENT* 
Treatment 
Phosphorylase a, Glycogen, 
N (%) N (mg/g) 
Control 4”: 14.2 * 0.8 2’: 3.49 rt 0.09 
Thyroxin (500 ug/day, 14-20 days) 32.8 * 2.0 2.19 f 0.13 
Nethalide (10 mg/kg, 30 min) 11.6 * 1.3 3.56 + 0.26 
Thyroxin + nethalide 
: 
22.3 & 1.7 
!: 
1.82 + 0.22 
Reserpine (2.5 mg/kg, 12 hr) 23 12.0 * 0.3 19 5.55 f 0.27 
Thyroxin + reserpine 20 14.7 * 1.2 12 2.57 f 0.20 
Trimethidinium (50 mg/kg, 12 hr) 14” 11.4 -1: 0.8 13” 3.24 i 0.34 
Thyroxin + trimethidinium 31.6 i 1.6 2.12 & 0.21 
* For both tables, values are means 1 SE. ; N equals number of animals per treatment. 
Thyroxin vs. control, P CO.01 (phosphorylase a and glycogen). Thyroxin + nethalide vs. 
control or thyroxin, P <OX)01 (phosphorylase a). Thyroxin -t reserpine vs. thyroxin, 
P <O.OOl (phosphorylase a). Reserpine VS. control, P cO.05. 
of thyroxin-treated animals produced by certain agents capable of blocking or reducing 
cardiac response to sympathomimetic agents. The data clearly demonstrate that thy- 
roxin treatment alone elevated phosphorylase a levels in the heart and markedly 
reduced cardiac glycogen. Total phosphorylase activity in the heart was unchanged by 
thyroxin pretreatment. Cardiac phosphorylase a levels were elevated if the thyroxin 
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treatment was shortened to 1 week at the same dose level (500 pg/‘day) or the amount 
of thyroxin administered daily was reduced to 50 pg (Fig. I). The glycogen levels in 
the hearts of animals receiving the lower dose of thyroxin were not significantly 
different from untreated controls, while at the higher dose level (500 pg,‘day for 1 
week) there was a significant fall in cardiac glycogen. 
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FIG. 1. The effect of norepinephrine (1.0 and 2.0 pg/kg . min-l) on phosphorylase a and glycogen 
content of rat heart in animals receiving thyroxin at two dose levels (500 pg/day for 1 week and 50 
&day for 2 weeks). Control animals received the alkaline saline solvent daily. Those animals not 
infused with norepinephrine were given an equal volume of bisulfite-saline solution. The data are 
plotted as mean values I_ S.E. The numbers in parentheses indicate the number of animals per 
treatment. All phosphorylase a increases after the thyroxin treatments are significantly different 
from untreated control (P (0.02). The glycogen value after thyroxin treatment (500 pg/day for I 
week) is significantly different from control (P cO.02). Interaction of 2 pg norepinephrine/kg and 
thyroxin (50 pg) and 1.0 and 2.0 ALg norepinephrine and 500 pg thyroxin was significant at the 
P CO.05 level for phosphorylase a. For glycogen loss, interaction of thyroxin (50~~) and 1.0 and 
2.0 pg norepinephrine was significant at P cO.05. 
Treatment of the thyrotoxic animals with the /3-adrenergic blocking agent, nethalide, 
in doses which were capable of blocking completely the action of exogenously ad- 
ministered catecholamine on phosphorylase Q levels, caused a partial reduction of the 
thyroxin-induced elevation of cardiac phosphorylase a levels (Table 1). While phos- 
phorylase a levels in hearts of thyrotoxic animals were reduced by the ,8-blocking 
agent, myocardial glycogen levels were not higher than those receiving only thyroxin. 
Hearts from thyroxin-treated rats contained 2.19 mg glycogen/g; and after nethalide 
treatment in thyrotoxic animals the glycogen was I.82 mglg, not significantly dif- 
ferent from thyroxin alone (Table I). Nethalide did not influence the cardiac phos- 
phorylase a or glycogen levels in untreated control animals. 
The effects of reserpine on heart phosphorylase a and glycogen levels in the normal 
rat have been previously reported. 14 From the earlier study and the data presented 
here it would appear that reserpine treatment does significantly reduce phosphorylase 
a levels, although this reduction is barely significant (Table 1). In these animals this 
dose of reserpine produced a marked elevation in cardiac glycogen, considerably 
in excess of that anticipated, considering the minimal reduction in phosphorylase a. 
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Treatment of the thyrotoxic rat with reserpine, under conditions which largely deplete 
the myocardium of catecholamines, completely abolished the thyroxin-induced eleva- 
tion in phosphorylase a. However, the cardiac glycogen level of the thyrotoxic rat was 
unchanged by reserpine treatment even though there was ample time for glycogen 
synthesis. 
To determine whether or not the thyroxin-induced elevation of cardiac phosphory- 
lase u originated from reflex effects, thyroxin-treated rats were given trimethidinium 
bismethosulfate, a long-acting ganglion blocking agent. The dose of trimethidinium 
administered has been shown in our laboratory to produce long-lasting blockade 
in the rat. Failure to reduce the phosphorylase a levels with this drug (Table 1) made 
it appear unlikely that the thyroid-induced increased phosphorylase a was either 
mediated reflexly or was secondary to central stimulation, since such effects should 
normally be abolished by ganglionic blockade. 
Effect of norepinephrine infusion on cardiac phosphorylase a and glycogen levels of 
thyroxin-treated rats 
Phosphorylase a and glycogen levels after norepinephrine infusion were determined 
in four groups: (1) untreated controls; (2) animals treated with 500 pg thyroxin for 
14-20 days; (3) animals receiving 2.5 mg reserpine/kg 12 hr previously; and (4) ani- 
mals receiving both the thyroxin and reserpine treatments. The data from these 
experiments are shown in Table 2 and the log dose-response plot for these data is 
TABLE 2. THE EFFECT OF NOREPINEPHRINE INFUSION ON CARDIAC PHOSPHORYLASE A 
AND GLYCOGEN LEVELS AFTER VARIOUS TREATMENTS 
Treatment 
Phosphorylase a d From d From 
N (%) control N G?z?n m control 
1. Saline control 
+ Norepinephrine 
0.5 rg/kg . min (5 min) 
1.0 pgg/kg . min (5 min) 
2.0 rg/kg . min (5 min) 
2. Thyroxin (500 pg/day) 
14-20 days 
+ Norepinephrine 
0.5 rg/kg . min (5 min) 
1 .O rg/kg . min (5 min) 
2.0 rg/kg . min (5 min) 
3. Reserpine 
2.5 mg/kg (12 hr) 
+ Norepinephrine 
0.5 pg/kg . min (5 min) 
1 .O pg/kg . min (5 min) 
2.0 rg/kg . min (5 min) 
4. Thyroxin -I- reserpine 
(treatment as above) 
i- Norepinephrine 
0.5 rg/kg . min (5 min) 
1.0 pg/kg * min (5 min) 
2.0 pg/kg . min (5 min) 
43 14.2 !-- 0.8 
8 11.6 1: 1.2 
:: 21.5 32 3 + & 2.5 1 6
43 32.8 & 2.0 
1; 36.4 i 4.3 
8 
23 12.0 + 0.3 
1;: 19.5 7.7 + .I: 1.8 I.4 
9 32.5 .L 3.4 
20 14.7 1. 1.2 
33 
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* Interaction of thyroxin and norepinephrine, P cO.05, compared to euthyroid animals. 
t Interaction of thyroxin and norepinephrine, P cO.05, compared to reserpine-treated animals. 
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illustrated in Fig. 2. Reference points for control values (i.e. those animals pretreated 
as above but infused with saline rather than norepinephrine) are indicated by the 
unbroken horizontal bars in Fit. 2. 
In euthyroid animals, the lowest dose of norepinephrine infused (0.5 ~g;kg~min -1) 
for 5 min did not produce a significant rise in cardiac phosphorylase n or a decrease 
FIG. 2. Graph of the log dose---response curves for I-norepinephrine-induced rat heart phosphorylase 
I 
03 CO zo 
NorepinephriRe uglkg. rnin-’ 
a activity. The curves are plotted from the data in Table 2. The control mean phosphorylase levels 
(also from Table 2) for each treatment are shown as horizontal bars on the ordinate. The slopes of 
ali four lines are not signi~cantly different from one another. 
in glycogen levels (Table 2). At the two larger doses of norepinephrine, phosphory- 
lase a levels rose from 14 to 21 and 33 per cent respectively. Only at the highest dose 
of norepinephrine (2.0 t”.gjkg.min) was cardiac glycogen significantly reduced. After 
thyroxin, the infusion of the same three concentrations of Ilorepil~ephrille produced 
phosphorylase a values of 36, 53 and 58 per cent respectively. Glycogen was signifi- 
cantly reduced after all doses of norepinephrine. An analysis of these data for inter- 
action of thyroxin and norepinephrine revealed a positive interaction which could be 
indicative of potentiation at the I.0 jhg’kg dose for phosphorylase a and at the two 
highest doses of ilorepil~ephrine for glycogen. The purpose of presenting the data 
appearing in Table 2 in graphic form (Fig. 2) was to determine the nature of the 
dose-response curve after the various treatments. After thyroxin and norepinephrine 
the slope of the dose-response curve did not appear to be different from that obtained 
after ~~orepinephril~e in euthyroid animals. It is apparent from the graph, however, 
that the norepinephrine log dose-response curve is shifted to the left in the thyroxin- 
treated animals. It may also be noted that the phosphorylase a value obtained at the 
highest dose of norepinephrine in these animals appears to be low (Table 2, Fig. 2) 
and may indicate a maximum which is artificially imposed upon the assay system, 
making it difhcult to obtain phosp~lory~ase a values above 60 %.I7 
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Potentiation of the norepinephrine-induced increase of phosphorylase a by thy- 
roxin may also be illustrated in animals which, in addition, were treated with reser- 
pine (Table 2). Euthyroid animals infused with the usual concentration of norepine- 
phrine after reserpine showed no unusual response. At 1-O and 2.0 &kg:min the 
per cent phosphorylase a levels rose 7.5 and 20.5 respectively. The data were quite 
comparable to those seen in the control series. However, when thyroxin-treated ani- 
mals received reserpine 12 hr previously and were then challenged with norepine- 
phrine, a potentiation of the norepinephrine infusion was unmasked, the per cent 
phosphorylase a levels rising by 13.5, 28.0, and 37 at the three norepinephrine con- 
centrations. Analysis of these data showed a positive interaction of thyroxin treat- 
ment and norepinephrine at all dose levels of norepinephrine (Table 2). A similar 
interaction was also demonstrated for glycogen loss at the two higher norepinephrine 
levels. 
Effect of various thyroxin treatments on phosphorylase a and glycogen levels 
Altering the dose and time schedule of thyroxin produced changes that were not 
markedly different from those observed after the administration of 500 pg/day for 
14 to 20 days (Fig. 1). It may be observed, however, that the rise in phosphorylase a 
in both these thyroxin-treated groups was lower than that observed with the original 
thyrotoxic group. Animals receiving 500 pglday for 1 week had cardiac phosphorylase 
a levels of 24 per cent (compared to 18 per cent for this control series) while those 
animals receiving 50 pg/day of I-thyroxin for 2 weeks had phosphorylase a levels of 
26 per cent. When these groups of animals were challenged with norepinephrine 
(1.0 and 2.0 rLg/kg.min) an enhanced phosphorylase a level was observed. Significant 
interaction of thyroxin and norepinephrine was demonstrated for the 50 pg/day 
thyroxin animals at a dose of 2 pg norepinephrine/kg and for both doses of norepine- 
phrine in those animals receiving 500 pg/l-thyroxin day for I week. 
A reduced cardiac glycogen was seen in those animals receiving 500 pg thyroxin/ 
day for 1 week. Because of this reduced level it was not possible to show potentiation 
of glycogen loss after norepinephrine infusion. However, in the group of animals 
receiving 50 pg thyroxin/day for 2 weeks such a potentiation could be demonstrated 
at both dose levels of norepinephrine. 
l?@ect of norepinephrine infusion on cardiac phosphorylase a and glycogen levels in 
triiodothyronine-treated rats 
In this study, rats were made thyrotoxic by the daily administration of 100 pg 
of triiodothyronine for 3-5 days. As was observed with thyroxin treatment, these 
animals showed a marked cardiac hypertrophy. This group of animals (Fig. 3) also 
showed a marked increase in cardiac phosphorylase a activity, having values of 
28 per cent. The response to infused norepinephrine is also observed in Fig. 3. Sig- 
nificant potentiation of the norepinephrine-induced increase in phosphorylase a 
could only be shown at the 1 pg/kg*min infusion levels. Figure 4 illustrates the glycogen 
changes measured in the same hearts as those in which the phosphorylase a values 
were shown after triiodothyronine in the previous figure. While this hormone did not 
appear to lower the cardiac glycogen levels significantly when compared to hearts 
from control animals, the fall in glycogen after norepinephrine infusion was markedly 
potentiated at all infusion rates. 









FIG. 3. Effect of norepinephrine infusion on cardiac phosphorylase n activity in triiodothyronine- 
treated rats. Triiodothyronine dose was 100 pg daily for 3-5 days. Numbers on the bar graphs 
indicate the number of animals in each group and the bars represent the mean values + S.E. Values 
of animals receiving triiodothyronine alone were significantly higher than those of the control group 
receiving alkaline saline instead of triiodothyronine. Interaction of triiodothyronine and 1.0 pg 
norepinephrine significant at P CO.05 for the phosphorylase a levels. 
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FIG. 4. Effect of norepinephrine infusion on rat cardiac glycogen content in triiodothyronine-treated 
animals. Drug treatment as in Fig. 3. Bars indicate the mean values :t S.E., and the numbers within 
the bars indicate the animals per group. Those animals receiving triiodothyronine alone had glycogen 
values not significantly different from controls. For glycogen loss, interaction of triiodothyronine 
and norepinephrine was significant (P CO.05) at all dose levels. 
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FIG. 5. Effect of norepinephrine infusion on cardiac phosphorylase a activity in thyroidectomized 
rats. Controls were not significantly different from sham-operated, but both groups were significantly 
higher than the thyroidectomized animals (P <O.Ol). Responses to infused norepinephrine were 
not different from those seen with the untreated control group except at the highest dose of norepine- 
phrine where significant interaction was demonstrated (P cO.05) in the thyroidectomized animals. 
Bars represent mean values & S.E. 
cl CONTROL 




FIG. 6. Effect of norepinephrine infusion on rat cardiac glycogen content in thyroidectomized rats. 
Cardiac glycogen was significantly higher in thyroidectomized animals than in control or sham- 
operated rats given saline (P cO.01). Only at the level of 20rg norepinephrine/kg was there significant 
interaction (P cO.05). 
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EfSect of norepinephrine infusion on cardiac phosphorylase a and glycogen lel>els iti the 
thyroidectomized rats 
Phosphorylase a values in the hearts of thyroidectomized animals were 9 %. which 
was significantly lower (P < 0.01) than either the sham-operated group or the un- 
treated controls. These data are shown in Fig. 5. However, the cardiac phosphorylase 
a response to infused norepinephrine was not different from that observed in un- 
treated controls. Only at the very large dose of norepinephrine (20 pg/kg.min) did 
there appear to be any significant difference in response between thyroidectomized 
animals and untreated controls. The small number of animals (3) in this latter series 
results from the fact that this dose of norepinephrine when infused for 5 min caused 
death in more than half the animals. Thyroidectomized animals can apparently toler- 
ate this amount of norepinephrine. 
The cardiac glycogen data also reflected changes similar to those seen in phos- 
phorylase a levels in thyroidectomized animals (Fig. 6). While glycogen levels are 
significantly higher than in untreated controls the glycogen levels in response to 
infused epinephrine do not appear to be reduced to a greater extent after thyroid- 
ectomy. Again, only at toxic levels of norepinephrine (20 pg/kg.min) was there any 
enhancement of the effect on glycogen. Analysis of these data failed to show an 
interaction (inhibition) to the norepinephrine response after thyroidectomy either 
with respect to cardiac phosphorylase a or glycogen. 
DISCUSSION 
From the data presented in this study it may be observed that the mean control 
phosphorylase a levels were approximately 14.2 per cent, with a standard error of 
0.8 per cent for the largest group of rats studied. This compares favourably with 
values in the literature for excised rat heart and skeletal muscle phosphorylase a 
levels, although lower values for perfused tissues and tissues frozen in situ have been 
reported. This has been discussed in detail elsewhere. While only negligible phos- 
phorylase a values have been reported for dog hearts2t by Wollenberger et al, more 
recently Drummond et a1,22 using the technique described by Wollenberger, reported 
phosphorylase a values of 3.6 per cent for the dog heart (open-chest preparation) and 
IO.8 per cent for perfused rat heart. 
That the increase in myocardial phosphorylase a levels in thyrotoxic rat might 
result from anoxia, as has been suggested, is negated by the fact that the tissue to be 
analyzed is frozen 4 set after opening the chest wall. The phosphorylase a response 
reported by Wollenberger et aLzl in dogs differed in the hyperthyroid animal only 
after an ischemic period of at least 15 sec. 
The nature of myocardial response in thyrotoxicosis is a problem which has 
generated a considerable degree of controversy since it was reported that the major 
cardiovascular and metabolic effects of thyroxin could be abolished by sympathetic 
blockade and subsequently restored by the infusion of catecholamines. Since the 
original observations of Brewster,’ similar types of studies have been reported in 
thyrotoxic animals and in man by the use of drugs which produce either myocardial 
catecholamine depletions, 12 or prevent the nervous release of these neurohumors.lO,ll 
On the basis of these and other findings it has been variously proposed that the sym- 
pathetic effect on the heart is to increase the availability of the catecholamines to the 
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myocardial receptors. This may be accomplished by decreasing nonreactive binding 
or uptake,gp r3 by altering the metabolism of the catecholamines,as-2s or by delivering 
an increased fraction of the cardiac output to the heart via the coronary vessels.13 
That these actions probably do not explain the mechanism of action of thyroid 
hormone is suggested by studies of catecholamine excretion in animals, where no 
change271 2s or only a moderate increase29 has been observed; or in hyperthyroid 
subjects where significant increases in catecholamine excretion have not been demon- 
strated.303 31 Observations of circulating epinephrine and norepinephrine have also 
shown no abnormal plasma levels elevation at rest or with exercise in hyperthyroid 
individuals (J. H. Siegel, unpublished observations), although elevated plasma levels 
have been observed in the thyrotoxic rat.26 
While the possibility has also been entertained that thyroid hormone acts by 
decreasing the tissue-binding capacity for catecholamines or by decreasing the 
activity or the tissue content of enzymes which normally metabolize these neuro- 
humors, Beaven et al32 found no increase in tissue norepinephrine turnover with 
thyroxin. Further, the present data show that reset-pine, which blocks myocardial 
catecholamine binding, abolishes the thyroxin-induced myocardial activation of 
phosphorylase but appears to allow the potentiation by thyroxin of exogenously 
administered norepinephrine. In addition, it seems unlikely that a decrease in mono- 
amine oxidase or o-methyl transferase activity is of major consequence in thyroid 
action, since Hornbrook and Brodyr4 have shown that drug-induced inhibition of 
monoamine oxidase resulted in elevated myocardial levels of catecholamines and 
failed to influence phosphorylase a levels. It was also observed that cardiac catechola- 
mine content is actually lowered by thyroid hormone treatment.143 32 
The present observations would appear to support the hypothesis that thyroid 
hormone modifies the response of the catecholamine receptors.19 33-36 The view that 
hypersensitivity of the receptor site is induced by thyroid hormone is supported by the 
observation that in thyroxin-treated animals there is an increase in myocardial phos- 
phorylase a activity and, more important, a potentiation of the norepinephrine- 
induced increase in phosphorylase a levels. This potentiation action is more marked 
after reserpine, since control levels are reduced. This theory of thyroid action is also 
supported by the data that a /I-adrenergic blocking agent, nethalide, is capable of 
reducing the thyroxin-induced increase in phosphorylase a activity. That this agent 
does not completely abolish the adrenergic effects of thyroxin may reflect the com- 
petitive nature of the drug. However, the existence of a nonadrenergic, reserpine- 
sensitive system cannot be ruled out by these data. 
Although reserpine caused an increase in cardiac glycogen in untreated control 
rats, those animals receiving both thyroxin and reserpine had cardiac glycogen 
levels which were not significantly different from those animals receiving only thyroxin. 
An earlier study indicated that myocardial glycogen can be repleted in 30 min from 
the low level resulting from catecholamine administration.14 The results obtained with 
combined thyroxin and reserpine treatment suggest the possibility of a thyroxin 
effect on myocardial glycogen, which is independent of the phosphorylase a level or 
the presence of catecholamines. This may represent a direct action of thyroxin on the 
enzymatic systems essential for glycogen synthesis or on the activities of other rate- 
limiting enzymes of the glycolytic pathway, such as phosphofructokinase, allowing 
the glycogen level to be maintained at a lower steady-state value.379 38 
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Thus, the effect of thyroid hormone on the heart appears to be secondary to its 
effect upon the catecholamine receptor. Thyroxin itself appears to have no independent 
ability to increase phosphorylase a activity when the catecholamines are depleted by 
reserpine. In the hyperthyroid animal after reserpine, norepinephrine produces a 
potentiation of cardiac phosphorylase a levels. 
In the thyroidectomized animal, however, while the magnitude of the norepine- 
phrine response is unaltered, the base line is reduced. The failure to demonstrate a 
reduction in response to norepinephrine in thyroidectomized animals is not entirely 
inconsistent with the hypothesis that thyroid hormone regulates phosphorylase 
activation. It may be that this effect occurs only at elevated thyroid hormone levels 
so that at normal or subnormal hormone levels the enzyme is unaffected. 
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